ClinicalTrials.gg
CompletedNCT06877234ModulationHTN1Updated Nov 10, 2026

Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN(FIM)

An interventional study of Ultrasonic Nerve Ablation System in Essential Hypertension, sponsored by Shenzhen Pulsecare Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Shenzhen Pulsecare Medical Technology Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2024, registered Mar 2025).
Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.

Enrollment
65th of 67
10 · median 297
Started
2024
with 7 others
No phase
22 of 76
8 open now
Registered
65th of 76
by date

Among the 76 studies in Essential Hypertension with a site in China, this one is the 65th largest by enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2024, is one of 22 with no phase, and was the 65th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Essential Hypertension with a site in China, or all of them as a file.
02

Study summary

This study is a prospective and exploratory clinical study, enrolling patients with essential hypertension. This study is planned to be conducted in 2 research institutions in China, and a total of 6 subjects are planned to be included. After the subjects sign the informed consent form (ICF) approved by the ethics committee, they will enter the screening procedure. Subjects who meet the inclusion criteria and do not meet any of the clinical exclusion criteria will be enrolled after undergoing renal artery CTA angiography.

All patients will undergo clinical evaluation and blood pressure measurement during the operation, at the time of discharge, and at 1 month, 2 months, 3 months, and 6 months after the operation.

It is recommended that the anti-hypertensive medications used before the operation should not be changed within 6 months after the operation for the cases. When the systolic blood pressure (SBP) is ≥ 180 mmHg or there are clinical symptoms caused by hypertension, the drug dosage should be increased as a priority, and then the anti-hypertensive medications should be adjusted. When the systolic blood pressure (SBP) is ≤ 120 mmHg or there are clinical symptoms caused by a decrease in blood pressure, the anti-hypertensive medications should be reduced.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Males or females aged 18 years old or above and 65 years old or below; Patients with essential hypertension; Patients who have been stably taking 2 or more antihypertensive drugs at conventional doses continuously for at least 4 weeks before enrollment, and whose blood pressure meets the following conditions: (1) The systolic blood pressure measured in the outpatient clinic is ≥150 mmHg and ≤180 mmHg, and the diastolic blood pressure measured in the outpatient clinic is ≥90 mmHg; (2) The systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) is between 135 mmHg and 170 mmHg; The course of hypertension is more than 6 months; The diameter of the renal artery evaluated by renal artery CTA is ≥3 mm and the length is ≥20 mm; The patient or his/her legal representative signs a written form approved by the ethics committee before screening;

Exclusion criteria

Exclusion Criteria:

Complicated with type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (defined as plasma Hb1Ac ≥ 10.0%); Estimated (eGFR) \< 45 mL/min/1.73 m²; Previous implantation of an implantable cardioverter-defibrillator (ICD) or a pacemaker; History of myocardial infarction, syncope, intracerebral hemorrhage or cerebral infarction within 6 months before signing the form; Severe valvular heart stenosis; Any factors that may interfere with blood pressure measurement under any circumstances (for example, the patient has severe peripheral vascular disease, abdominal aortic aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia, severe anemia); Patients with sleep apnea syndrome; Females who are pregnant or breastfeeding, or those who have a plan to conceive within the next year; Other serious organic diseases with an expected lifespan of less than 12 months; Participation in other clinical trials before screening and not yet completed;

Preoperative exclusion criteria based on CTA imaging:

a. Visual inspection shows that the diameter stenosis of the renal artery on either side > 50% or there is a renal artery aneurysm on either side; b. Previous history of renal artery interventional treatment; Other situations that the investigator deems unsuitable for enrollment.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Exploratory Clinical Study of the Ultrasound Nerve Ablation System

    Procedure: Ultrasonic Nerve Ablation System

Interventions

  • ProcedureUltrasonic Nerve Ablation System

    Treatment of patients with essential hypertension using the ultrasonic nerve ablation system

06

What researchers measure

Primary outcomes

  1. The change in the average daytime systolic blood pressure two months after the operation

    That is, the difference between the average daytime (from 7:00 to 22:00) systolic blood pressure measured before the operation and the average daytime systolic blood pressure measured during the follow-up visit two months after the operation

    Time frame: Two months after the operation

  2. Major adverse events within 30 days after the operation

    Major adverse events include: all-cause mortality, renal complications, renal artery embolism events, complications of interventional treatment, hypertensive/hypotensive crises during hospitalization, and major cardiovascular and cerebrovascular complications.

    Time frame: Within 30 days after the operation

Secondary outcomes

  1. The changes in the average systolic blood pressure of ambulatory blood pressure during the daytime, at night and over 24 hours after the operation

    Changes in the average systolic blood pressure of ambulatory blood pressure during the daytime, at night and over 24 hours after the operation (1 month, 3 months, 6 months) That is, the difference between the average systolic blood pressure of ambulatory blood pressure measured during the daytime (7:00-22:00), at night (22:00-7:00) and over 24 hours before the operation and the average systolic blood pressure of ambulatory blood pressure measured during the daytime, at night and over 24 hours during the postoperative follow-up.

    Time frame: 1 month, 3 months, 6 months after the operation

  2. Changes in the average diastolic blood pressure of ambulatory blood pressure during the daytime, at night and over 24 hours after the operation

    That is, the difference between the average diastolic blood pressure of ambulatory blood pressure measured during the daytime (7:00-22:00), at night (22:00-7:00) and over 24 hours before the operation, and the average diastolic blood pressure of ambulatory blood pressure measured during the daytime, at night and over 24 hours during the postoperative follow-up

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  3. The attainment rate of systolic blood pressure reaching the standard in the outpatient clinic after the operation

    That is, the proportion of subjects whose systolic blood pressure measured in the outpatient clinic during the postoperative follow-up is less than 140 mmHg.

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  4. The change in systolic blood pressure measured in the outpatient clinic after the operation

    That is, the difference between the systolic blood pressure measured in the outpatient clinic before the operation and the systolic blood pressure measured in the outpatient clinic during the postoperative follow-up

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  5. The average number of types of medications taken after the operation

    The change in the average number of types of medications taken during the postoperative follow-up period, compared with the antihypertensive medications taken before the operation.

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  6. The incidence rate of complications of interventional treatment

    It refers to the intraoperative or postoperative related complications that occur after the research device has completed the renal artery ultrasound ablation surgery, such as renal artery perforation, renal artery dissection, acute infection, etc

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  7. All-cause mortality rate

    Death caused by any reason as informed during the clinical follow-up

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  8. Cardiovascular and cerebrovascular complications

    It refers to myocardial infarction, any stroke event (including intracerebral hemorrhage and cerebral infarction), and any coronary revascularization

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  9. Renal complications

    Refers to eGFR \<15 mL/min/1.73㎡, requirement for renal replacement therapy, or renal artery revascularization; renal artery stenosis (refers to diameter stenosis ≥50%).

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  10. The incidence rate of adverse events and serious adverse events

    The number of adverse events and serious adverse events

    Time frame: 1 month, 2 months, 3 months, 6 months after the operation

  11. The incidence rate of device defects.

    The number of occurrences of device defects

    Time frame: during the operation

07

Study locations

1 site
  • the Second Affiliated Hospital of Sun Yat-sen University (Sun Yat-sen Memorial Hospital)
    Guangzhou, Guangdong 510120, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jul 2025, 11 months.

Of 80 interventional studies with no phase under Essential Hypertension, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's 11 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2025 → Jul 2025 and completion Mar 2026 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Aug 8, 2024
Primary completionActual
Jul 29, 2025was Dec 2025
CompletionActual
Jul 29, 2025was Mar 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Dec 2025→Jul 29, 2025 (actual)
Nov 10, 2026
Study completion
Mar 2026→Jul 29, 2025 (actual)
Nov 10, 2026
Enrollment
6 (estimated)→10 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Dec 2025→Jul 29, 2025 (now actual)
    Study completion Mar 2026→Jul 29, 2025 (now actual)
    Enrollment 6 (estimated)→10 (actual)
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06877234
Lead sponsor
Shenzhen Pulsecare Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Aug 8, 2024
Primary completion
Jul 29, 2025
Completion
Jul 29, 2025
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion